



EXPRESS MAIL NO. EV34701162105

#91A 28
02/23/03
RECEIVED
JUN 24 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Davin C. Dillon et al.
Application No. : 10/010,742
Filed : November 30, 2001
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND
DIAGNOSIS OF BREAST CANCER

Examiner : Teresa E. Strzelecka
Art Unit : 1637
Docket No. : 210121.491C7
Date : June 20, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT
AND PRELIMINARY AMENDMENT

Commissioner for Patents:

In response to the Restriction Requirement dated April 15, 2003, please extend the period of time for response two (2) months, to expire on July 15, 2003. Enclosed are a Petition for an Extension of Time and the requisite fee.

Applicants hereby elect Group I, claims 1, 3, 4, 8, and 15, directed to an isolated polynucleotide, oligonucleotides that hybridize to the polynucleotide, and kits comprising the polynucleotide. Applicants further elect species, SEQ ID NO:305, the polynucleotide sequence that encodes the amino acid sequence set forth in SEQ ID NO: 307, also referred to as B854P.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.